ArticleFrontiers in microbiology2026
Single-center clinical laboratory evaluation of VITEK REVEAL for rapid phenotypic antimicrobial susceptibility testing of Gram-negative organisms directly from positive blood cultures.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Rapid phenotypic antimicrobial susceptibility testing (AST) has the potential to support earlier optimization of antimicrobial therapy for patients with bloodstream infections. We evaluated the real-world clinical laboratory performance of the bioMérieux VITEK REVEAL® rapid phenotypic AST system using positive blood cultures containing Gram-negative (GN) organisms and compared its results with those obtained using the routine standard-of-care (SOC) MicroScan WalkAway Plus system. Methods: A total of 200 positive blood culture bottles yielding GN organisms were evaluated. VITEK REVEAL® performance was assessed using categorical agreement (CA), essential agreement (EA), and error rates, including very major errors (VMEs), major errors (MEs), and minor errors (mEs), with the MicroScan serving as the comparator method. The Etest was performed as a supplemental exploratory method to evaluate selected VME and ME discrepancies. Results: Within the local resistance epidemiology represented in this study, VITEK REVEAL showed ≥90% EA across evaluated antimicrobial-organism combinations and ≥90% CA for all combinations except amoxicillin/clavulanate (AMC) and ampicillin/sulbactam (SAM). Across the 2,536 antimicrobial-organism combinations evaluated, 14 VMEs (0.6%), 16 MEs (0.6%), and 82 mEs (3.3%) were observed. Several elevated error rates were associated with limited numbers of resistant isolates and breakpoint-adjacent minimum inhibitory concentration (MIC) distributions. Supplemental Etest analysis reduced the number of selected discrepancies, although reference broth microdilution was not performed. Conclusion: This single-center study was designed as a real-world comparative clinical laboratory evaluation and is limited by the use of an automated comparator method rather than reference broth microdilution, the local resistance epidemiology, and limited isolate numbers for certain antimicrobial-organism combinations. By providing phenotypic AST results directly from positive blood cultures in less than 8 h, VITEK REVEAL may support earlier therapeutic decision-making and antimicrobial stewardship efforts. Additional multicenter and clinical outcome studies are needed to better determine its clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.